Yamashita Yugo, Takagi Daisuke, Hamatani Yasuhiro, Iguchi Moritake, Masunaga Nobutoyo, Esato Masahiro, Chun Yeong-Hwa, Itoh Hitoshi, Nishimura Masato, Wada Hiromichi, Hasegawa Koji, Ogawa Hisashi, Abe Mitsuru, Akao Masaharu
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Cardiology, National Hospital Organization Kyoto Medical Center, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan.
Heart Vessels. 2016 Dec;31(12):2025-2034. doi: 10.1007/s00380-016-0818-x. Epub 2016 Mar 14.
Atrial fibrillation (AF) is common in dialysis patients. However, clinical characteristics and outcomes of dialysis patients with AF are poorly understood. The Fushimi AF Registry is a community-based prospective survey of AF patients in Japan. Follow-up data were available for 3713 patients with a median follow-up of 2.8 years. We compared clinical characteristics and outcomes between the dialysis group (n = 92; 2.5 %) and others. The dialysis group had more various co-morbidities, with a mean CHADS score of 2.5, and the rate of warfarin prescription was 38 %. The annual incidence rates of stroke or systemic embolism (SE), major bleeding, and all-cause death in the dialysis group were 4.0, 5.1, and 20.9 per 100 person-years, respectively. There was no significant difference in the incidence rate of stroke/SE between the dialysis group and the non-dialysis group [hazard ratio (HR) 1.74 (95 % confidence interval (CI) 0.74-3.42)]. The incidence rates of major bleeding, all-cause death, and the composite of stroke/SE and all-cause death in the dialysis group were higher than those in the non-dialysis group [major bleeding: HR 3.09 (95 % CI 1.46-5.72), all-cause death: HR 3.51 (95 % CI 2.48-4.81), the composite of stroke/SE and all-cause death: HR 2.99 (95 % CI 2.15-4.05)]. Among dialysis patients, warfarin did not affect major clinical events including stroke/SE, bleeding or all-cause death. Among AF patients, those receiving dialysis showed higher incidence of major bleeding and all-cause death compared with non-dialysis patients, but the risk of stroke/SE was not particularly high.
心房颤动(AF)在透析患者中很常见。然而,对于透析合并AF患者的临床特征和预后了解甚少。伏见AF注册研究是一项针对日本AF患者的基于社区的前瞻性调查。共有3713例患者有随访数据,中位随访时间为2.8年。我们比较了透析组(n = 92;2.5%)和其他组的临床特征及预后。透析组有更多种合并症,平均CHADS评分为2.5,华法林处方率为38%。透析组中风或全身性栓塞(SE)、大出血和全因死亡的年发生率分别为每100人年4.0、5.1和20.9例。透析组与非透析组之间中风/SE的发生率无显著差异[风险比(HR)1.74(95%置信区间(CI)0.74 - 3.42)]。透析组大出血、全因死亡以及中风/SE和全因死亡复合事件的发生率高于非透析组[大出血:HR 3.09(95%CI 1.46 - 5.72),全因死亡:HR 3.51(95%CI 2.48 - 4.81),中风/SE和全因死亡复合事件:HR 2.99(95%CI 2.15 - 4.05)]。在透析患者中,华法林不影响包括中风/SE、出血或全因死亡在内的主要临床事件。在AF患者中,与非透析患者相比,接受透析的患者大出血和全因死亡的发生率更高,但中风/SE的风险并非特别高。